Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Is the Growth Rate of the Oral Biologics & Biosimilars Market?

The market size for oral biologics & biosimilars has seen substantial growth in the past few years. The size is projected to increase from $7.04 billion in 2024 to $8.69 billion in 2025, witnessing a compound annual growth rate (CAGR) of 23.5%. The notable growth during the historical period is attributed to the enhanced collaborations and partnerships among market participants for improved understanding, the rising necessity for immunology, amplified demand encouraged by the cost-efficient production process, an aging demographic, governmental initiatives, and the capacity to dictate high prices.

What Growth Rate Is Forecasted for the Oral Biologics & Biosimilars Market by 2029?

It is anticipated that the market size for oral biologics & biosimilars will witness a significant expansion in the approaching years, estimated to reach $19.13 billion by 2029 with a compound annual growth rate (CAGR) of 21.8%. The predicted surge during the forecast period can be traced back to several factors such as robust R&D efforts in the field of oral biologics, preference for pills over injections, the rise in unhealthy lifestyles, technological advancements, the convenience of using oral biologics, improved access to healthcare, broader reimbursement for biologics, the escalation in biosimilars, and the increasing prevalence of chronic conditions. Key market trends for the projected period comprise investments in the oral biologics market for potential high-profit margins, the transition towards biologics due to the growing rate of innovation in the sector, and the production of microneedle injectors-based medications to enhance bioavailability while negating side effects of the subcutaneous route.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=6830&type=smp

Which Key Companies Are Shaping the Future of the Oral Biologics & Biosimilars Market?

Major companies operating in the oral biologics & biosimilars market include Merck & Co. Inc., GlaxoSmithKline, Novo Nordisk, ALK-Abelló, Aimmune Therapeutics Inc., VIVUS Inc, Materia Medica Holding, VECTOR-MEDICA, Henlius, Innovent Biologics, Bio-Thera, Hisun Pharma, 3SBio, Beijing ShuangLu Pharmaceuticals, Qilu Pharmaceutical, Shanghai Fosun Pharmaceuticals, Biocon, Dr.Reddy’s, Mylan, Kyowa Hakko Kirin, Takeda, Mitsubishi Tanabe, AGC Biologics, BiosanaPharma, AstraZeneca, Bayer, Boehringer Ingelheim, Sanofi, Microgen, Geropharm, Valenta, NovaMedica, SynBio, Roche, Rani Therapeutics, Eli Lilly and Company, Emisphere Technologies Inc., Enteris BioPharma, Allena Pharmaceuticals, Abbvie, Johnson & Johnson, Pfizer Inc., Biogen Inc., Aché, Eurofarma, Teva Pharmaceuticals, Oramed Pharmaceuticals, Entera Bio, Julphar, Hikma Pharmaceuticals, Altis Biologics, Cipla Medpro South Africa, Genzyme

Which Factors Are Driving Demand in the Oral Biologics & Biosimilars Industry?

The increasing incidence of chronic illnesses like arthritis, asthma, and cancer is believed to be a major driving force behind the expansion of the oral biologics and biosimilar market. The growth of such illnesses can be attributed to factors such as long work hours, insufficient physical exercise, and poor dietary and drinking habits, and the use of biologics to treat these conditions is on the rise. Biologics assist the immune system in targeting cancer cells, supporting the body’s natural defenses in eliminating harmful cells. A United Nations article from a US-based intergovernmental organization forecasts that by 2030, chronic diseases will be responsible for 70% of all global deaths. It is also predicted that these diseases will account for nearly 60% of all global mortalities. Thus, the escalating incidence of these conditions is fuelling the development of the biologics and biosimilar market.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=6830&type=smp

How Is the Oral Biologics & Biosimilars Market Segmented by Several Divisions?

The oral biologics & biosimilars market covered in this report is segmented –

1) By Therapy: Lymphocyte Modulators, Interleukin Inhibitors, Tumor Necrosis Factor-Alpha Inhibitors, Immunostimulants, GPCR Modulators, Other Tharpies

2) By Disease: Diabetes, Arthritis and Crohn’s Disease, Cancer, Infectious Disease, Other Autoimmune Disease, Other Diseases

3) By Molecule Type: Vaccines, Proteins and Peptides, Monoclonal Antibodies, Other Molecule Types

4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

Subsegments:

1) By Lymphocyte Modulators: T-Cell Modulators, B-Cell Modulators, Sphingosine-1-Phosphate Receptor Modulators

2) By Interleukin Inhibitors: IL-1 Inhibitors, IL-6 Inhibitors, IL-17 Inhibitors, IL-23 Inhibitors

3) By Tumor Necrosis Factor-Alpha Inhibitors: TNF-α Blockers, Monoclonal Antibodies Targeting TNF-α

4) By Immunostimulants: Cytokines, Immune Checkpoint Inhibitors, Adjuvants

5) By GPCR Modulators: Agonists, Antagonists, Biased Ligands

6) By Other Therapies: Cell-Based Therapies, Gene Therapies, Combination Therapies

What are the Emerging Market Trends Driving the Growth of the Oral Biologics & Biosimilars Industry?

The rise in production of new insulin biosimilars is an emerging trend that is gaining ground in the oral biologics and biosimilar market. Major players in the sector are investing in this area, producing biosimilars of insulin to increase their market presence. An example of this came in January 2023 when Amgen, a U.S. biotechnology firm, introduced Amjevita, a biosimilar to Humira, reflecting progress in insulin biosimilar development. Their goal is to reduce expenditures and enhance access to essential therapies. Amjevita offers a more cost-effective alternative for ailments such as arthritis and Crohn’s disease, making diabetes treatments with insulin biosimilars more economical and accessible. These advancements intensify competition and stimulate innovation in biologics. The company’s mission is to discover, develop, manufacture and provide innovative human therapeutics.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/oral-biologics-and-biosimilars-global-market-report

Which Regions Are Driving Growth in the Oral Biologics & Biosimilars Market?

North America was the largest region in the oral biologics and biosimilar drugs market in 2024. The Middle East is expected to be the fastest-growing region in the forecast period. The regions covered in the oral biologics & biosimilars market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=6830

This Report Delivers Insight On:

1. How big is the oral biologics & biosimilars market, and how is it changing globally?

2. Who are the major companies in the oral biologics & biosimilars market, and how are they performing?

3. What are the key opportunities and risks in the oral biologics & biosimilars market right now?

4. Which products or customer segments are growing the most in the oral biologics & biosimilars market?

5. What factors are helping or slowing down the growth of the oral biologics & biosimilars market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 2071930708

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model